Blastomycosis Market by Drug Type (Azoles, Polyenes and Others), Distribution Channel (Hospital and Clinical Pharmacy, Online Pharmacy and Retail Pharmacy), Formulation (Tablets, Ointment, Powder and Liquid) and Geography (North America, Europe, APAC and RoW)- Forecast up to 2027

Blastomycosis Market by Drug Type (Azoles, Polyenes and Others), Distribution Channel (Hospital and Clinical Pharmacy, Online Pharmacy and Retail Pharmacy), Formulation (Tablets, Ointment, Powder and Liquid) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027

Blastomycosis a fungal infection is caused due to the organism known as Blastomyces dermatitidis. Blastomyces dermatitidis grows in wood and soil. When inhaled, the follicle of Blastomyces goes into the body through the air, majorly affecting the lungs and causing pneumonia. Then, the fungi spread to other parts of body through the bloodstream. Blastomycosis can affect any host; however, it is more extreme in people with weakened immune systems. Key factors propelling the growth of the blastomycosis market are an increase in the development of new medicine for the treatment of blastomycosis infection, a rise in the occurrence rate of chronic diseases such as tuberculosis, pneumonia, a non-infectious pulmonary disease which have resulted in increase in a number of blastomycosis patients, and increased adoption of azoles for the treatment of blastomycosis. Additionally, the rise in the incidence and prevalence rate of infectious diseases and the increase in the population of immunocompromised individuals augment the growth of this market. However, adverse reimbursements as well as complications of medicine and drugs may hamper the market growth. The Blastomycosis Market is likely to grow at a rate of 3.8% CAGR by 2027.

Blastomycosis Market by Drug Type

• Azoles

• Polyenes

• Others

Blastomycosis Market by Distribution Channel

• Hospital and Clinical Pharmacy

• Online Pharmacy

• Retail Pharmacy

Blastomycosis Market by Formulation

• Tablets

• Ointment

• Powder

• Liquid

Blastomycosis Market by Geography

• North America

• Europe

• Asia Pacific

• Rest of the World

The Blastomycosis market by drug type is divided into Azoles, Polyenes and Others. Among which the azoles segment is holding the maximum share of the market. This is due to the surge in the number of fungal infections such as candidiasis, blastomycosis, and immunological disease and an increase in the awareness about the usage of azole drug for the treatment of blastomycosis. The rise of the azoles segment is also due to a rise in the usage of azole drugs in combination with another drug for a synergistic effect.

Accordance to the distribution channel, the market is bifurcated into Hospital and Clinical Pharmacy, Online Pharmacy and Retail Pharmacy. The Hospital and Clinical Pharmacy segment is accounted for the highest share in the market. The highest share of the segment is ascribed to the fact that a surge in demand for precise drugs as per the status of blastomycosis, and a rise in demand for consultation about the dosing of blastomycosis medicine.

As in the Formulation segmentation, the market is categorized as Tablets, Ointment, Powder and Liquid. The liquid segment holds the maximum share in the market. The factors such as the increased adoption of liquid formulations for the treatment of blastomycosis fungal infection, and the rise in the prevalence of fungal infection are responsible for the maximum share of the segment. Moreover, the surge in the need for quick onset of action in the treatment of blastomycosis has accelerated the growth of the liquid segment.

The regional market is divided into North America, Europe, Asia Pacific and rest of the world. The North America region is the largest contributor in the market growth. This is due to the surge in the number of fungal infection cases, existence of leading players, advancements in healthcare in the region, strong healthcare infrastructure and increase in healthcare expenditure.

The expansion of the global blastomycosis market can be ascribed to the soaring cases of blastomycosis. In addition to this, the rising outdoor activities and poor diets across the globe are also projected to add to the market growth. In addition to these, factors that are believed to boost the market growth of blastomycosis treatment include the increase in poor lifestyles.

The market report provides the few notable companies include Pfizer Inc., johnson and johnson md&d, Merck and Company, CELON LABORATORIES LIMITED, Astellas Pharma Inc., Sanofi, GSK, Abbott Laboratories, Sun Pharmaceuticals Ltd and Cipla Ltd.

Henceforth, the blastomycosis market is likely to grow at a rapid pace. This is because of the fact that, it is estimated that blastomycosis disease is highly prevalent in the Africa and Middle East where the market for blastomycosis has a significant expansion.

• This report defines, describes and forecasts the market by drug type, distribution channel, formulation and geography.

• This report gives complete details regarding the vital factors influencing the growth of the market.

• The report strategically analyzes the market in terms of individual growth trends, future prospects and the contribution of each segment to the market

• This report tracks and scrutinizes the competitive developments in market which include contracts & agreements, new product launches, expansions & investments, and partnerships and collaborations.

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Drug Type: Market Size & Analysis
5.1. Overview
5.2. Azoles
5.3. Polyenes
5.4. Others
6. Distribution Channel: Market Size & Analysis
6.1. Overview
6.2. Hospital and Clinical Pharmacy
6.3. Online Pharmacy
6.4. Retail Pharmacy
7. Formulation: Market Size & Analysis
7.1. Overview
7.2. Tablets
7.3. Ointment
7.4. Powder
7.5. Liquid
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Pfizer Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. johnson and johnson md&d
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Merck and Company
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. CELON LABORATORIES LIMITED
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Astellas Pharma Inc.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Sanofi
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. GSK
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Abbott Laboratories
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Sun Pharmaceuticals Ltd
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Cipla Ltd
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

TABLE 1. GLOBAL BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR AZOLES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR POLYENES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR HOSPITAL AND CLINICAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR ONLINE PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR TABLETS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR OINTMENT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR POWDER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL BLASTOMYCOSIS MARKET VALUE FOR LIQUID, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA BLASTOMYCOSIS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. NORTH AMERICA BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 18. U.S BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 19. U.S BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. U.S BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 21. CANADA BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 22. CANADA BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. CANADA BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 24. EUROPE BLASTOMYCOSIS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 25. EUROPE BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 26. EUROPE BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. EUROPE BLASTOMYCOSIS MARKET VALUE, FORMULATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 29. GERMANY BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. GERMANY BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 31. U.K BLASTOMYCOSIS  MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 32. U.K BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. U.K BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 34. FRANCE BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 35. FRANCE BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. FRANCE BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 37. ITALY BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 38. ITALY BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. ITALY BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 40. SPAIN BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 41. SPAIN BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. SPAIN BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 43. ROE BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 44. ROE BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ROE BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC BLASTOMYCOSIS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. ASIA PACIFC BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 50. CHINA BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 51. CHINA BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. CHINA BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 53. INDIA BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 54. INDIA BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. INDIA BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 56. JAPAN BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 57. JAPAN BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. JAPAN BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF APAC BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD BLASTOMYCOSIS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD BLASTOMYCOSIS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. REST OF WORLD BLASTOMYCOSIS MARKET VALUE, BY FORMULATION, 2021-2027 (USD BILLION)
TABLE 65. PFIZER INC.: FINANCIALS 
TABLE 66. PFIZER INC.: PRODUCTS & SERVICES 
TABLE 67. PFIZER INC.: RECENT DEVELOPMENTS 
TABLE 68. JOHNSON AND JOHNSON MD&D: FINANCIALS 
TABLE 69. JOHNSON AND JOHNSON MD&D: PRODUCTS & SERVICES 
TABLE 70. JOHNSON AND JOHNSON MD&D: RECENT DEVELOPMENTS 
TABLE 71. MERCK AND COMPANY: FINANCIALS 
TABLE 72. MERCK AND COMPANY: PRODUCTS & SERVICES 
TABLE 73. MERCK AND COMPANY: RECENT DEVELOPMENTS 
TABLE 74. CELON LABORATORIES LIMITED: FINANCIALS 
TABLE 75. CELON LABORATORIES LIMITED: PRODUCTS & SERVICES 
TABLE 76. CELON LABORATORIES LIMITED: RECENT DEVELOPMENTS 
TABLE 77. ASTELLAS PHARMA INC.: FINANCIALS 
TABLE 78. ASTELLAS PHARMA INC.: PRODUCTS & SERVICES 
TABLE 79. ASTELLAS PHARMA INC.: RECENT DEVELOPMENTS 
TABLE 80. SANOFI: FINANCIALS 
TABLE 81. SANOFI: PRODUCTS & SERVICES 
TABLE 82. SANOFI: RECENT DEVELOPMENTS 
TABLE 83. GSK: FINANCIALS 
TABLE 84. GSK: PRODUCTS & SERVICES 
TABLE 85. GSK: RECENT DEVELOPMENTS 
TABLE 86. ABBOTT LABORATORIES: FINANCIALS 
TABLE 87. ABBOTT LABORATORIES: PRODUCTS & SERVICES 
TABLE 88. ABBOTT LABORATORIES: RECENT DEVELOPMENTS 
TABLE 89. SUN PHARMACEUTICALS LTD: FINANCIALS 
TABLE 90. SUN PHARMACEUTICALS LTD: PRODUCTS & SERVICES 
TABLE 91. SUN PHARMACEUTICALS LTD: RECENT DEVELOPMENTS 
TABLE 92. CIPLA LTD: FINANCIALS 
TABLE 93. CIPLA LTD: PRODUCTS & SERVICES 
TABLE 94. CIPLA LTD: RECENT DEVELOPMENTS

Name*

Email ID*

Company*

Phone (With Country Code)*

What is/are your question(s)?:

Publisher: IHR Insights

Related Reports

Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)

Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)

Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035

Why Market Study Report?

Best Price for Reports
Large Report Database
Easily Customize Reports
24/7 Email & Phone Support